trending Market Intelligence /marketintelligence/en/news-insights/trending/PklnXCKGZJm5jBL7Ht-I1Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Horizon Pharma secures preliminary patent approval for urea disorder drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Horizon Pharma secures preliminary patent approval for urea disorder drug

Horizon Pharma PLC secured preliminary approval for a U.S. patent that would cover its Ravicti oral treatment for urea cycle disorders in patients older than two years of age.

The U.S. Patent and Trademark Office issued a notice of allowance for the patent that would expire on Sept. 22, 2030, once granted.